Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Accumulated Expenses (2022 - 2025)

NewAmsterdam Pharma's Accumulated Expenses history spans 4 years, with the latest figure at $9.4 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 7.27% year-over-year to $9.4 million; the TTM value through Dec 2025 reached $9.4 million, up 7.27%, while the annual FY2025 figure was $9.4 million, 7.27% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $9.4 million at NewAmsterdam Pharma, up from $5.9 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $9.4 million in Q4 2025 and bottomed at $1.1 million in Q1 2024.
  • The 4-year median for Accumulated Expenses is $3.6 million (2023), against an average of $4.3 million.
  • The largest annual shift saw Accumulated Expenses surged 157.71% in 2024 before it grew 7.27% in 2025.
  • A 4-year view of Accumulated Expenses shows it stood at $2.0 million in 2022, then skyrocketed by 69.37% to $3.4 million in 2023, then skyrocketed by 157.71% to $8.7 million in 2024, then rose by 7.27% to $9.4 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Accumulated Expenses are $9.4 million (Q4 2025), $5.9 million (Q3 2025), and $3.8 million (Q2 2025).